JP7358365B2 - がんを治療するための、化学療法剤と併用した多量体抗ｄｒ５結合分子の使用 - Google Patents

がんを治療するための、化学療法剤と併用した多量体抗ｄｒ５結合分子の使用 Download PDF

Info

Publication number
JP7358365B2
JP7358365B2 JP2020543140A JP2020543140A JP7358365B2 JP 7358365 B2 JP7358365 B2 JP 7358365B2 JP 2020543140 A JP2020543140 A JP 2020543140A JP 2020543140 A JP2020543140 A JP 2020543140A JP 7358365 B2 JP7358365 B2 JP 7358365B2
Authority
JP
Japan
Prior art keywords
seq
binding
igm
domain
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020543140A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514945A5 (https=
JP2021514945A (ja
JPWO2019165340A5 (https=
Inventor
ベアトリス ティエン－イ ワン
ブルース アラン キート
Original Assignee
アイジーエム バイオサイエンシズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイジーエム バイオサイエンシズ インコーポレイテッド filed Critical アイジーエム バイオサイエンシズ インコーポレイテッド
Publication of JP2021514945A publication Critical patent/JP2021514945A/ja
Publication of JP2021514945A5 publication Critical patent/JP2021514945A5/ja
Publication of JPWO2019165340A5 publication Critical patent/JPWO2019165340A5/ja
Priority to JP2023138517A priority Critical patent/JP2023159403A/ja
Application granted granted Critical
Publication of JP7358365B2 publication Critical patent/JP7358365B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020543140A 2018-02-26 2019-02-25 がんを治療するための、化学療法剤と併用した多量体抗ｄｒ５結合分子の使用 Active JP7358365B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023138517A JP2023159403A (ja) 2018-02-26 2023-08-29 がんを治療するための、化学療法剤と併用した多量体抗ｄｒ５結合分子の使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862635033P 2018-02-26 2018-02-26
US62/635,033 2018-02-26
US201862767900P 2018-11-15 2018-11-15
US62/767,900 2018-11-15
PCT/US2019/019340 WO2019165340A1 (en) 2018-02-26 2019-02-25 Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023138517A Division JP2023159403A (ja) 2018-02-26 2023-08-29 がんを治療するための、化学療法剤と併用した多量体抗ｄｒ５結合分子の使用

Publications (4)

Publication Number Publication Date
JP2021514945A JP2021514945A (ja) 2021-06-17
JP2021514945A5 JP2021514945A5 (https=) 2022-02-18
JPWO2019165340A5 JPWO2019165340A5 (https=) 2022-02-18
JP7358365B2 true JP7358365B2 (ja) 2023-10-10

Family

ID=67688449

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020543140A Active JP7358365B2 (ja) 2018-02-26 2019-02-25 がんを治療するための、化学療法剤と併用した多量体抗ｄｒ５結合分子の使用
JP2023138517A Pending JP2023159403A (ja) 2018-02-26 2023-08-29 がんを治療するための、化学療法剤と併用した多量体抗ｄｒ５結合分子の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023138517A Pending JP2023159403A (ja) 2018-02-26 2023-08-29 がんを治療するための、化学療法剤と併用した多量体抗ｄｒ５結合分子の使用

Country Status (8)

Country Link
US (1) US20200392239A1 (https=)
EP (1) EP3759229A4 (https=)
JP (2) JP7358365B2 (https=)
KR (1) KR20200123782A (https=)
CN (1) CN111757941A (https=)
AU (1) AU2019224136A1 (https=)
CA (1) CA3091140A1 (https=)
WO (1) WO2019165340A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017512208A (ja) 2014-02-10 2017-05-18 アイジーエム バイオサイエンス， インコーポレイテッド ＩｇＡ多重特異性結合分子
IL292311A (en) 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
PT3247728T (pt) 2015-01-20 2020-07-16 Igm Biosciences Inc Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
KR102357312B1 (ko) 2015-03-04 2022-02-03 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄ20 결합 분자 및 그의 용도
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
WO2016168758A1 (en) 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
EP3824903A1 (en) 2015-09-30 2021-05-26 IGM Biosciences Inc. Binding molecules with modified j-chain
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
JP6979971B2 (ja) 2016-05-09 2021-12-15 アイジーエム バイオサイエンシズ インコーポレイテッド 抗ｐｄ−ｌ１抗体
US11401337B2 (en) 2017-04-07 2022-08-02 Igm Biosciences, Inc. Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
CN111787951B (zh) 2018-03-01 2025-06-17 Igm生物科学股份有限公司 影响IgM血清半衰期的IgM Fc和J链突变
MX2022001934A (es) 2019-08-15 2022-03-11 Igm Biosciences Inc Moleculas de union multimericas inmunoestimuladoras.
BR112022021392A2 (pt) 2020-04-22 2022-12-06 Igm Biosciences Inc Moléculas de ligação multiméricas de agonista de pd-1
JP2023526224A (ja) * 2020-05-12 2023-06-21 アイジーエム バイオサイエンシズ インコーポレイテッド がんを治療するための、がん治療薬との組合せでの多量体抗ｄｒ５結合分子の使用
WO2022154664A1 (en) * 2021-01-15 2022-07-21 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer
US12600801B2 (en) 2022-07-11 2026-04-14 Fred Hutchinson Cancer Center Single-domain antibodies that bind ROR1

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008066854A2 (en) 2006-11-28 2008-06-05 Novartis Ag Methods and compositions for inducing apoptosis in cancer cells
WO2009020093A1 (ja) 2007-08-09 2009-02-12 Daiichi Sankyo Company, Limited デスドメイン含有受容体発現細胞にアポトーシスを誘導するイムノリポソーム
JP2009505676A (ja) 2005-08-31 2009-02-12 アムジエン・インコーポレーテツド Ｔｒａｉｌ受容体２ポリペプチダーゼ及び抗体
WO2012057288A1 (ja) 2010-10-29 2012-05-03 第一三共株式会社 新規抗ｄｒ５抗体
JP2015501291A (ja) 2011-09-26 2015-01-15 ジェイエヌ バイオサイエンシーズ エルエルシー ハイブリッド定常領域
JP2015527992A (ja) 2012-07-09 2015-09-24 アンテルナショナル−ドラック−ディベロップメント−バイオテック 抗−ｄｒ５ファミリー抗体、二重特異性又は多価の抗−ｄｒ５ファミリー抗体及びそれらの使用方法
WO2017059387A1 (en) 2015-09-30 2017-04-06 Igm Biosciences, Inc. Binding molecules with modified j-chain
JP2018503401A (ja) 2015-01-20 2018-02-08 アイジーエム バイオサイエンシズ インコーポレイテッド 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080248046A1 (en) * 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
CN100427505C (zh) * 2004-08-19 2008-10-22 中国医学科学院基础医学研究所 抗人肿瘤坏死因子相关凋亡诱导配体的受体dr5单克隆抗体（ad5-10）及其制法与用途
ES2812208T3 (es) * 2013-03-14 2021-03-16 Bristol Myers Squibb Co Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009505676A (ja) 2005-08-31 2009-02-12 アムジエン・インコーポレーテツド Ｔｒａｉｌ受容体２ポリペプチダーゼ及び抗体
WO2008066854A2 (en) 2006-11-28 2008-06-05 Novartis Ag Methods and compositions for inducing apoptosis in cancer cells
WO2009020093A1 (ja) 2007-08-09 2009-02-12 Daiichi Sankyo Company, Limited デスドメイン含有受容体発現細胞にアポトーシスを誘導するイムノリポソーム
WO2012057288A1 (ja) 2010-10-29 2012-05-03 第一三共株式会社 新規抗ｄｒ５抗体
JP2015501291A (ja) 2011-09-26 2015-01-15 ジェイエヌ バイオサイエンシーズ エルエルシー ハイブリッド定常領域
JP2015527992A (ja) 2012-07-09 2015-09-24 アンテルナショナル−ドラック−ディベロップメント−バイオテック 抗−ｄｒ５ファミリー抗体、二重特異性又は多価の抗−ｄｒ５ファミリー抗体及びそれらの使用方法
JP2018503401A (ja) 2015-01-20 2018-02-08 アイジーエム バイオサイエンシズ インコーポレイテッド 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用
WO2017059387A1 (en) 2015-09-30 2017-04-06 Igm Biosciences, Inc. Binding molecules with modified j-chain

Also Published As

Publication number Publication date
CA3091140A1 (en) 2019-08-29
CN111757941A (zh) 2020-10-09
JP2023159403A (ja) 2023-10-31
KR20200123782A (ko) 2020-10-30
JP2021514945A (ja) 2021-06-17
AU2019224136A1 (en) 2020-09-10
WO2019165340A1 (en) 2019-08-29
EP3759229A1 (en) 2021-01-06
US20200392239A1 (en) 2020-12-17
EP3759229A4 (en) 2021-12-29

Similar Documents

Publication Publication Date Title
JP7358365B2 (ja) がんを治療するための、化学療法剤と併用した多量体抗ｄｒ５結合分子の使用
US20230203173A1 (en) Tumor necrosis factor (tnf) superfamily receptor igm antibodies and uses thereof
US20230174660A1 (en) Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer
BR112017018941B1 (pt) Molécula de ligação a cd20, seu uso, composição e método in vitro para direcionar a morte mediada por complemento de uma célula que expressa cd20
WO2023178253A2 (en) Use of a multimeric anti-pd-l1 binding molecule in combination with a monoclonal antibody therapy
JP2025506341A (ja) 抗ｃｄ３８結合分子及びその使用
HK40043005A (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
CA2972990C (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
HK1242348B (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
HK1242348A1 (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200817

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220208

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230301

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230829

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230906

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230926

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230927

R150 Certificate of patent or registration of utility model

Ref document number: 7358365

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150